Approximately half of all pancreatic cysts are neoplastic, mainly comprising intraductal papillary mucinous neoplasms (IPMN), which can progress to invasive carcinoma. Current Fukuoka guidelines have limited sensitivity and specificity in predicting progression of asymptomatic pancreatic cysts. We present first results of the prospective ZYSTEUS biomarker study investigating (i) whether detection of driver mutations in IPMN by liquid biopsy is technically feasible, (ii) which compartment of IPMN is most suitable for analysis, and (iii) implications for clinical diagnostics. Twenty-two patients with clinical inclusion criteria were enrolled in ZYSTEUS. Fifteen cases underwent endoscopic ultrasound (EUS)-guided fine-needle aspiration and cytological diagnostics. Cellular and liquid fraction of the cysts of each case were separated and subjected to deep targeted next generation sequencing (NGS). Clinical parameters, imaging findings (EUS and MRI), and follow-up data were collected continuously. All IPMN cases (n = 12) showed at least one mutation in either KRAS (n = 11) or GNAS (n = 4). Three cases showed both KRAS and GNAS mutations. Six cases harbored multiple KRAS/GNAS mutations. In the three cases with pseudocysts, no KRAS or GNAS mutations were detected. DNA yields were higher and showed higher mutation diversity in the cellular fraction. In conclusion, mutation detection in pancreatic cyst fluid is technically feasible with more robust results in the cellular than in the liquid fraction. Current results suggest that, together with imaging, targeted sequencing supports discrimination of IPMN from pseudocysts. The prospective design of ZYSTEUS will provide insight into diagnostic value of NGS in preoperative risk stratification. Our data provide evidence for an oligoclonal nature of IPMN.
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Cytology shows higher specificity, but may be less sensitive since cyst fluid sent for cytology provides adequate cellular material for analysis in less than 50% of the cases. 13, 14 As CEA levels and cytology of cyst fluid have insufficient sensitivity and specificity predicting mucinous dysplasia respectively invasive cancer, improvement of preoperative diagnostic methods is needed. Molecular genetic analysis of pancreatic cyst fluid is a new but rapidly evolving method to identify oncogenic driver mutations that might serve as a surrogate marker to identify or to predict high grade lesions. However, data on the performance and value of this approach are still limited and heterogeneous as varied methods being used. 15, 16 In the present study, we report interim results of the prospective ZYSTEUS study that was designed to investigate technical feasibility, suitability of input material, as well as the diagnostic and prognostic role of deep targeted Next Generation Sequencing (NGS) 17 of EUSguided fine needle aspirated cyst fluid (cellular fraction and liquid fraction) of patients with mucinous pancreatic cysts greater than 8 mm.
| PATIENTS AND METHODS

| Patients
The prospective ZYSTEUS (Cyst [ 
| Clinical data, imaging, and EUS-procedure
The clinical data, which included age, gender, and symptoms related to pancreatic cyst, were recorded in standard fashion. All information on patient demographics is provided in 
| Data analysis
After base calling, the reads were aligned against the human genome Variant annotation was performed using Annovar. 19 Annotations included information about nucleotide and amino acid changes of RefSeq annotated genes, COSMIC, and dbSNP entries as well as possible splice site mutations. For data interpretation and verification, the aligned reads were visualized using the IGV browser (Broad Institute, Boston, USA). 20 For the colon cfDNA panel, the raw data were processed by the implemented Torrent Suite Software (version 5.6) using the cfDNA variant caller plugin supplied by Thermo Fisher Scientific with parameters optimized for the Oncology-Liquid Biopsy application and use of tag sequencing technology. 3 | RESULTS
| Microsatellite stability assessment by IHC
| Cohort characteristics
Until now, 22 patients ( Figure 1 ) were prospectively enrolled for EUS guided fine needle aspiration/biopsy, but six patients dropped out as they refused the procedure. In one patient, biopsy revealed mucinous adenocarcinoma in a cyst next to the aspirated cyst fluid. This patient was excluded as he already had overt malignancy. The final patient cohort consisted of 15 patients for which EUS guided fine needle aspiration/biopsy was available. Of the 15 cases which underwent molecular profiling, 48% were male ( Table 1 ). The median age was 70 AE 8 years. In two IPMN cases, more than one cyst was punctured and analyzed. For patient 12, three independent cysts were punctured and analyzed. The cysts harbored one shared KRAS mutation detected in both liquid and cellular fraction of all cysts as well as two private KRAS and GNAS mutations, respectively. For the other patient (patient 10), two independent cysts of a multifocal branch duct IPMN were analyzed; in both cysts the liquid fraction contained very low amounts of cfDNA (<0.05 ng/μL; see Supporting Information Table S1 ). While the first cyst harbored a KRAS activating mutation, the second cyst revealed no mutations. DNA content of the cellular fraction of the second cyst was also very low (<0.05 ng/μL; see Supporting Information Table S1 ).
Besides case 8, all 12 IPMN cases showed at least one KRAS activating mutation in the cellular fraction of the pancreatic cysts ( Figure 3A) . During evolution toward adenocarcinoma one of these subclones may prevail while the others diminish due to limited fitness ( Figure 3B ). Data on disease progression of the lesions were not available at the time of publication for both patients. Of note, there was no case where the analysis of the liquid fraction revealed additional mutations when compared with the cellular fraction of the pancreatic cyst fluid. Moreover, mutations detected in the cellular fraction shedded into the cystic fluid were generally more diverse (for details see Table 2 ). For patient 3, separation into liquid and cellular phase was not possible (0.5 mL highly mucinous material) while in two other patients (patients 4 and 6), the liquid fraction revealed no mutations, although the cellular fraction was mutation positive.
In two cases the respective cysts were resected, thus the sequencing results of liquid biopsy and surgical specimen could be directly compared. In patient 2 (IPMN with medium-grade dysplasia),
we detected multiple KRAS mutations in the liquid biopsy and a low frequency (2% allele frequency) KRAS mutation p.G12D in the resected surgical specimen, which was also the most prominent KRAS mutation present in the cellular fraction of the liquid biopsy. In patient 6 (IPMN with low-grade dysplasia), we could not reproduce the low frequency KRAS activating mutation detected in the liquid biopsy when sequencing the resected surgical specimen. As the cyst from which the liquid was extracted was not marked (by, eg, biopsy clips) during the process, enrichment of the potentially KRAS-positive material was not possible. Both resection specimens were microsatellite stable (MSS) as detected by immunohistochemistry.
None of the three cases with acute pancreatitis and infected pseudocysts (patients 12-14) harbored a KRAS or GNAS activating mutation (Table 2) . However, in one of these cases a low frequency (<0.5% allele frequency) TP53 deleterious mutation was noted.
| DISCUSSION
Here, we report first data of the ZYSTEUS biomarker study, which was designed to prospectively investigate technical feasibility, suitability of the input material as well as the diagnostic and predictive value of deep targeted sequencing of pancreatic cyst material. The longterm goal of this prospective and ongoing study is to determine molecular parameters in cyst fluid that can-in conjunction with other already established diagnostic tools-improve distinction between non-neoplastic and neoplastic lesions as well as pre-operative prediction of the malignant potential of mucinous pancreatic cystic lesions.
While this question can only be satisfactorily addressed with sufficient cohort size and follow-up data, we here present in this feasibility study data on the liquid biopsies of the first 12 IPMN patients as well as three patients with pseudocysts serving as control cases, which were all consecutively included in this study.
In keeping with findings from previous studies using preoperative EUS guided fine needle biopsy specimen, we were able to detect KRAS and/or GNAS mutations in all pancreatic cyst aspirates.
The prevalence of KRAS mutations was high with only one negative IPMN and mirrors previous tissue based studies. [23] [24] [25] [26] [27] [28] Of note, we detected multiple KRAS mutations in 4 (33%) and multiple GNAS Abbreviations: AA exchange, amino acid exchange; mol Freq, molecular frequency based on molecular barcodes; mol BC, molecular barcodes; mol cov., molecular coverage based on molecular barcodes; NA, not available. Sample material was too viscous or too little to separate liquid and cellular fraction. Coverage and allelic frequencies derived from Ion reporter analyses can be found in Supporting Information Table S1 .
dysplasia. The frequency of events, however, is considerably higher than in the only other study describing this phenomenon. 16 Specifically, Singhi et al. described multiple KRAS or GNAS mutations in 7.14% (n = 4 out of 56 sequenced histopathologically determined IPMN). 16 They obtained cfDNA from the liquid fraction and used Ion Torrent NGS with a targeted panel specific for FFPE or cytology specimen. 16 Our higher detection rate may be explained by two aspects:
First, in addition to the liquid fraction of the cyst fluid, we also analyzed the cellular compartment shed into the cyst fluid. Second, the sensitivity of our NGS panel approach designed for liquid biopsies maybe higher. This panel employs molecular barcodes which label all DNA-molecules before amplification, thus combining insights into the true molecular frequencies of mutations with the advantage of amplification which has lower DNA input requirements than, for example, hybrid capture. Interestingly, the finding of multiple KRAS or GNAS mutations in a substantial proportion of cases indicates oligoclonal development of IPMN, which involves several subclones of major mutated driver genes ( Figure 3A) , We propose that further tumor evolution selects one of these as dominant founder clone, which will drive malignant behavior while the other driver subclones diminish over time due impaired fitness ( Figure 3B ). This proposal is line with the finding that the majority of pancreatic adenocarcinomas show only one truncal activating KRAS mutation, 29 which constitutes a driver sufficient for tumor development. Consequently, multiple KRAS mutations in one malignant tumor are rare. 30, 31 While the concept of a malignant polyclonal tumor comprising a truncal clone (usually harboring a mutant potent driver, such as KRAS) and multiple subclones was hypothesized Nowell in 1976 32 and is now well established, 33 our data extend this concept by demonstrating genetic heterogeneity already in a pre-malignant non-invasive tumor type. In the IPMN, we observed multiple independent potent driver clones (eg, multiple clones with activating KRAS mutations) possibly spatially distributed in the multifocal but communicating cystic lesions ( Figure 3A ). These findings are in keeping with reports that demonstrated KRAS activating mutations as common drivers not only in malignant 16, 25 but also in clinically benign neoplasias and premalignant 34, 35 tumors (eg, colonic tubular adenoma).
Some studies indicate that the detection of GNAS rather than KRAS mutations may be a predictor of IPMN development toward mucinous cystadenocarcinoma. 16 Table 2 ). Since additional sequencing of the liquid fraction did not reveal more but fewer mutations our data indicates that sequencing of the cellular fraction in the cystic fluid yields more robust and more comprehensive data and should be preferred. Lower DNA diversity in samples with low cfDNA content may lead to false negative results. In several patients, the liquid fraction showed lower mutation diversity or did not replicate the findings in the cellular fraction due to low cfDNA amounts (Supporting Information Table S1 ).
As this study is still ongoing, only two of our patients underwent surgery for cyst resection from which we could extract DNA for direct comparison of resection specimen and liquid biopsy. In one case (patient 2; IPMN with medium-grade dysplasia), we could confirm the mutation, which was present in both cellular and liquid fraction in the tissue specimen. This variant had the highest allelic frequency of the multiple detected KRAS-activating mutations. For the other case (patient 6; IPMN with low-grade dysplasia), we did not find the KRAS mutation which was detected in the cellular fraction of the cystic fluid with a frequency of 3.34%. As the punctured cysts were not marked during procedure, sampling error may have been introduced by other IPMN-related cysts in the sample. As liquid biopsy analysis using barcoded NGS represents a very sensitive method of mutation detection, we may be able to find a mutation far earlier than the actual malignant development of the cysts.
In both cases there was no evidence for invasive carcinoma. 
